MUMBAI, India, May 10, 2024 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2024.     Consolidated Financial Highlights (In INR Crores) Particulars Q4 FY24 Q4 FY23 YoY Growth FY24   FY23   YoY Growth Revenue from Operations 2,552 2,164 18 % 8,171 7,082 15 %    CDMO 1,649 1,281 29 % 4,750 4,001 19 %    Complex Hospital Generic (CHG) 667 702 (5) % 2,449 2,286 7 %    India Consumer Healthcare (ICH) 238 210 14 % 985 874 13 % EBITDA# 556 376 48 % 1,372 853 61 % EBITDA Margin 22 % 17 % 17 % 12 % PAT (before exceptional item) 132 50 163 % 81 (180) NA Exceptional Item* (31) 0 NA (63) (7) NA PAT (after exceptional item) 101 50 102 % 18 (186) NA # FY2023 EBITDA had one-time inventory margin impact of INR 68 Crores * Q4 FY24 Exceptional item of INR 31 Crores towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized     Key Highlights for Q4 and FY2024 Revenue from Operations grew by 18% YoY and 15% YoY in Q4FY24 and FY24 respectively, driven by healthy growth in our CDMO and ICH businesses EBITDA grew by 48% YoY and 61% YoY in Q4FY24 and FY24 respectively, primarily driven by revenue growth, operating leverage, cost optimization, and operational excellence initiatives Net Profit After Tax (before exceptional Items) more than doubled in Q4FY24 at INR 132 Crores compared to INR 50 Crores in Q4FY23 Net Debt / EBITDA improved from 5.6x at the start of the financial year to 2.9x at the end of FY24       Nandini Piramal, Chairperson, Piramal Pharma Limited said, "FY24 has been a strong year for the Company with all round improvement, mainly driven by our CDMO business that delivered a robust 19% YoY revenue growth. We saw significant increase in order inflows, especially for on-patent commercial manufacturing, amidst a difficult biotech funding environment. Contributions from our innovation related work and differentiated offerings also increased in FY24.  Capacity expansion at our Grangemouth facility for Antibody Drug Conjugate segment was commercialized and is seeing good customer interest. In the Inhalation anesthesia business, we continue to maintain our leading position in Sevoflurane in the US market and are expanding our capacities to tap the growing demand in the ROW markets. Our India Consumer Healthcare business is also continuing to perform well with focus on better EBITDA margin. During the year, we also showed a significant improvement in our profitability with EBITDA margin of 17% (Vs. 12% in FY23). All our three businesses delivered higher EBITDA margins through operating leverage, cost optimization, and operational excellence initiatives. Our Net Debt / EBITDA ratio also improved significantly, as we ended the financial year below 3x compared to 5.6x at the start of the year."        Key Business Highlights for Q4FY24 and FY24 Contract Development and Manufacturing Organization (CDMO): -  Strong Order Inflows: Despite challenging biotech funding environment, our new service order# inflows in FY24 were significantly higher compared to FY23, especially for commercial manufacturing of on-patent molecules -